- Home
- SIGA vs ERAS Comparison
SIGA vs ERAS Comparison
Compare SIGA & ERAS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SIGA
- ERAS
- Stock Information
- Founded
- SIGA 1995
- ERAS 2018
- Country
- SIGA United States
- ERAS United States
- Employees
- SIGA N/A
- ERAS N/A
- Industry
- SIGA Biotechnology: Pharmaceutical Preparations
- ERAS Biotechnology: Pharmaceutical Preparations
- Sector
- SIGA Health Care
- ERAS Health Care
- Exchange
- SIGA Nasdaq
- ERAS Nasdaq
- Market Cap
- SIGA 515.1M
- ERAS 484.4M
- IPO Year
- SIGA 1997
- ERAS 2021
- Fundamental
- Price
- SIGA $9.13
- ERAS $1.60
- Analyst Decision
- SIGA
- ERAS Strong Buy
- Analyst Count
- SIGA 0
- ERAS 6
- Target Price
- SIGA N/A
- ERAS $4.50
- AVG Volume (30 Days)
- SIGA 640.7K
- ERAS 749.3K
- Earning Date
- SIGA 08-05-2025
- ERAS 08-12-2025
- Dividend Yield
- SIGA 6.57%
- ERAS N/A
- EPS Growth
- SIGA N/A
- ERAS N/A
- EPS
- SIGA 1.14
- ERAS N/A
- Revenue
- SIGA $179,639,422.00
- ERAS N/A
- Revenue This Year
- SIGA N/A
- ERAS N/A
- Revenue Next Year
- SIGA $95.31
- ERAS N/A
- P/E Ratio
- SIGA $8.01
- ERAS N/A
- Revenue Growth
- SIGA 3.86
- ERAS N/A
- 52 Week Low
- SIGA $4.95
- ERAS $1.01
- 52 Week High
- SIGA $9.80
- ERAS $3.31
- Technical
- Relative Strength Index (RSI)
- SIGA 67.83
- ERAS 55.28
- Support Level
- SIGA $8.39
- ERAS $1.44
- Resistance Level
- SIGA $9.14
- ERAS $1.68
- Average True Range (ATR)
- SIGA 0.50
- ERAS 0.11
- MACD
- SIGA 0.04
- ERAS 0.00
- Stochastic Oscillator
- SIGA 84.19
- ERAS 67.69
About SIGA SIGA Technologies Inc.
SIGA Technologies Inc is a commercial-stage pharmaceutical company focused on the health security market. The company's main product is TPOXX, an oral formulation antiviral drug for the treatment of human smallpox disease caused by the variola virus. The company derives maximum revenue from United States.
About ERAS Erasca Inc.
Erasca Inc is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's product pipeline includes; Naporafenib, a pan-RAF inhibitor with first-in-class potential in NRASm melanoma, RAS Q61X tissue agnostic solid tumors, and other RAS/MAPK pathway-driven tumors, and ERAS-007 (oral ERK1/2 inhibitor) and ERAS-601 (oral SHP2 inhibitor), which target downstream and upstream nodes, respectively, of the RAS/MAPK pathway.